Austin, TX (PRWEB) July 31, 2013
Emergent Technologies, Inc., a leading innovation solutions company, and DiFusion Technologies, Inc., a pioneering orthobiologics company, announced today a strategic partnership in which Emergent will assist DiFusion in the launch of its proprietary suite of CleanFuze antimicrobial orthobiologic implants.
CleanFuze implants use DiFusion’s core technology, a novel biomaterial that resists infection and forms a direct and lasting connection with bone. This material uses Metallic Ions as Therapeutic Agents (MITA’s) to effect cellular signaling and both upstream and downstream cellular metabolic processes.
According the Centers for Disease Control and Prevention, hospital infections, including surgical site infections, are the fourth largest killer in the U.S., claiming more U.S. lives than AIDS, breast cancer and traffic accidents combined.
“DiFusion’s proven biofilm inhibition technology and strong patent position are a good fit for our Partner Solutions Model,” said Thomas Harlan, Chairman and CEO of Emergent Technologies. “Utilizing our model will help DiFusion accelerate successful market acceptance and deployment of its CleanFuze technology.”
Derrick Johns, DiFusion Founder and CEO commented, “We look forward to working with Emergent and leveraging the experience and expertise the company has developed over many years of successful technology commercialization and its numerous industry partnerships.”
DiFusion will launch its CleanFuze Xiphos™ spinal implant products in the European Union later
Copyright©2012 Vocus, Inc.
All rights reserved